Table 1 Characteristics of the study subjects
From: Usefulness of measurement of heart rate variability by holter ECG in hemodialysis patients
All patients (n = 90) | |
Age (year) | 63.4 ± 11.8 |
Gender (f/m) | 26:64 |
Duration of HD (months) | 68.4 ± 73.4 (1–328) |
Primary Cause of HD, n (%) | |
Diabetic Nephropathy | 44 (48.9%) |
Chronic glomerulonephritics | 30 (33.3%) |
Unknown or others | 16 (17.8%) |
Body Mass Index (kg/m2) | 21.6 ± 3.2 |
PVC,n (%) | 48 (53.3%) |
Medication, n (%) | |
ARB | 54 (60.0%) |
Beta blockers | 39 (43.3%) |
48 (53.3%) | Ca channel blockers |
ACE | 4 (4.4%) |
Hemoglobin (g/dl) | 10.1 ± 1.1 |
Albumin (g/dl) | 3.9 ± 0.5 |
pre/postHD Na (mEq/l) | 138.3 ± 3.5/139.9 ± 2.1 |
pre/postHD K (mEq/l) | 4.3 ± 0.7/3.3 ± 0.4 |
pre/postHD Ca (mg/dl) | 9.2 ± 1.3/9.5 ± 1.0 |
Fluid removal (kg) | 2.2 ± 1.2 |
Pre/post HD systolic blood pressure (mmHg) | 153.7 ± 19.1/122.3 ± 18.2 |
Pre/post HD diastolic blood pressure (mmHg) | 70.4 ± 14.3/73.1 ± 16.6 |